NASDAQ:BCAX Bicara Therapeutics (BCAX) Stock Price, News & Analysis $10.67 -0.44 (-3.98%) As of 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Bicara Therapeutics Stock (NASDAQ:BCAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bicara Therapeutics alerts:Sign Up Key Stats Today's Range$10.64▼$11.1750-Day Range$8.71▼$15.6652-Week Range$7.80▼$28.09Volume208,118 shsAverage Volume625,578 shsMarket Capitalization$583.75 millionP/E RatioN/ADividend YieldN/APrice Target$31.86Consensus RatingBuy Company Overview Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Read More Receive BCAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAX Stock News HeadlinesBicara Therapeutics Inc News (BCAX) - Investing.comJune 27, 2025 | investing.com# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trialJune 13, 2025 | investing.comWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? No gimmicks. No shady tricks. Just a powerful IRS-approved loophole that most Americans have never heard of. It's called a Self-Directed Gold IRA, and it's quietly becoming the go-to wealth protection strategy for people who see the writing on the wall. When you take the next step, you could qualify for up to $10,000 in FREE GOLD & SILVER with your purchase of a qualified account.August 1 at 2:00 AM | Advantage Gold (Ad)BCAX Bicara Therapeutics Inc.June 8, 2025 | seekingalpha.comBicara Therapeutics Expands Boston Headquarters with New LeaseJune 6, 2025 | tipranks.comBicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comBicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025June 1, 2025 | globenewswire.comStifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative PatientsMay 26, 2025 | insidermonkey.comSee More Headlines BCAX Stock Analysis - Frequently Asked Questions How have BCAX shares performed this year? Bicara Therapeutics' stock was trading at $17.42 at the start of the year. Since then, BCAX stock has decreased by 38.8% and is now trading at $10.6690. How were Bicara Therapeutics' earnings last quarter? Bicara Therapeutics Inc. (NASDAQ:BCAX) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.28. When did Bicara Therapeutics IPO? Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at $18.00 per share. Who are Bicara Therapeutics' major shareholders? Top institutional investors of Bicara Therapeutics include TD Asset Management Inc (0.41%) and Atle Fund Management AB (0.27%). View institutional ownership trends. How do I buy shares of Bicara Therapeutics? Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/13/2025Today8/01/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCAX Previous SymbolNASDAQ:BCAX CIK2023658 Webwww.bicara.com Phone(617) 468-4219FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Price Target for Bicara Therapeutics$31.86 High Price Target$48.00 Low Price Target$8.00 Potential Upside/Downside+186.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio24.62 Quick Ratio24.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.04 per share Price / Book1.23Miscellaneous Outstanding Shares54,536,000Free Float46,083,000Market Cap$605.89 million OptionableN/A BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:BCAX) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | SponsoredMusk's Big Prediction for 2025Elon Musk just made a bold prediction about 2025—and it could upend the entire tech sector. If he’s right, ...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.